




## Preparation

- Ensure that the vials are at room temperature (20-30°C).
- Remove flip top caps from product and Water for Injections (WFI) vial.
- Apply an appropriate antiseptic to both rubber stoppers and allow to dry.
- Remove lid of the Mix2Vial packaging.




## Step 1.

- **Place WFI vial upright on a level surface.**
- Pick up Mix2Vial in its outer packaging and invert it.
- Holding the WFI vial securely, push **blue** end of the Mix2Vial vertically down through the WFI vial stopper.




## Step 2.

- Carefully remove the Mix2Vial outer packaging.
- Ensure the Mix2Vial remains attached to the WFI vial.




## Step 3.

- **Place product vial upright on a level surface.**
- Invert the WFI vial with Mix2Vial attached.
- Holding the product vial securely, push clear end of the Mix2Vial vertically down through the product vial stopper.
- The Water for Injections will be drawn out of its vial and into the product vial by the vacuum within the product vial.



## Step 4.

- Leaving the system connected, gently swirl to ensure that the product is fully dissolved.
- Unscrew Mix2Vial into two separate pieces.
- Discard the WFI vial and blue end of the Mix2Vial.




## Step 5.

- Keeping product vial upright with clear end of the Mix2Vial attached, attach syringe.
- Invert system and draw reconstituted product into syringe.
- When product has been transferred, discard the Mix2Vial and product vial.



## IMPORTANT:



The Mix2Vial system must be connected vertically to a product vial placed upright and held securely on a level surface. If the Mix2Vial is connected at an angle, the vacuum may be released from the product vial and the WFI will not transfer into the product vial.

If you **have used** the Mix2Vial correctly as illustrated above, and the WFI has not transferred into the product vial, please return the Mix2Vial and both product and WFI vials to the Australian Red Cross Blood Service.

The Medicines Australia Code of Conduct defines standards for the content of materials produced, and the conduct of promotional activities undertaken, by pharmaceutical companies within Australia. As a member of Medicines Australia, CSL Bioplasma willingly complies with the Medicines Australia Code of Conduct ([www.medicinesaustralia.com.au](http://www.medicinesaustralia.com.au)).

**Before prescribing or administering a plasma-derived therapeutic manufactured by CSL Bioplasma that is packaged with Mix2Vial, please consult the approved Product Information or Consumer Medicine Information.**

CSL Limited, Bioplasma Division, 189 - 209 Camp Road, Broadmeadows, Victoria, 3047, Australia. ABN: 99 051 588 348

For Medical/Technical Inquiries: 1800 067 140 E-mail: [medicalaffairs\\_bioplasma@csl.com.au](mailto:medicalaffairs_bioplasma@csl.com.au)

For Customer Service Inquiries: 1800 063 892 E-mail: [bioplasma.customerservice@csl.com.au](mailto:bioplasma.customerservice@csl.com.au)

Internet: [www.cslbioplasma.com.au](http://www.cslbioplasma.com.au) <sup>TM</sup>Mix2Vial is a trade mark of Medimop Medical Projects Ltd.

or

Australian Red Cross Blood Service, ABN: 50 169 394 003 Contact the local Transfusion Medicine Specialist in your capital city.

Email: [clinicalinfo@arcbs.redcross.org.au](mailto:clinicalinfo@arcbs.redcross.org.au) Internet: [www.transfusion.com.au](http://www.transfusion.com.au)



# CSL Bioplasma